Originally founded in 1992, Cylex is a venture-backed
global life sciences company based in Columbia, Maryland. Cylex develops,
manufactures and commercializes in vitro diagnostic products
intended to illuminate immunity in the area of transplant medicine.
The Company received certification to ISO 13485:2003 and 9001:2000,
signifying compliance with internationally recognized standards in
design, development and manufacturing of medical products. Cylex
experienced exponential growth in recent years and holds a robust
portfolio of patents issued in North America, Europe and Asia.
Cylex’s first FDA-cleared product, ImmuKnow,
represents patented technology designed to give clinical researchers
insight for individualized patient management. Combined with individual
patients’ clinical factors and other routine monitoring tests, ImmuKnow
assay results help guide decisions in therapy to avoid over- or under-immunosuppression.
ImmuKnow is currently sold in 18 countries.